Human Immunology News Volume 10.02 | Jan 18 2022

    By
    Justin.choi
    -
    0
    46







    2022-01-18 | HIN 10.02


    Human Immunology News by STEMCELL Technologies
    Vol. 10.02 – 18 January, 2022
    TOP STORY

    Key Interactions in the Trimolecular Complex Consisting of the Rheumatoid Arthritis-Associated DRB1*04:01 Molecule, the Major Glycosylated Collagen II Peptide and the T Cell Receptor

    The crystal structures identified peptide binding to DRB1*04:01 and potential side chain exposure to T cells.
    [Annals of the Rheumatic Diseases]

    Abstract
    Scientific resources to support your immunology research. Learn More!
    PUBLICATIONSRanked by the impact factor of the journal

    A Subset of Follicular Helper-Like MAIT Cells Can Provide B Cell Help and Support Antibody Production in the Mucosa

    Researchers described a population of CXCR5+ T follicular helper–like mucosal-associated invariant T (MAIT) cells that have the capacity to provide B cell help within mucosal lymphoid organs.
    [Science Immunology]

    Abstract

    Boosting NAD+ Blunts Toll-Like Receptor-4 Induced Type-I Interferon in Control and Systemic Lupus Erythematosus Monocytes

    Scientists explored the underlying biology in myeloid cells from healthy volunteers following in vivo placebo or nicotinamide riboside administration and subsequently tested the findings in vitro in monocytes extracted from subjects with systemic lupus erythematosus.
    [Journal of Clinical Investigation]

    Abstract

    CD116+ Fetal Precursors Migrate to the Perinatal Lung and Give Rise to Human Alveolar Macrophages

    Investigators identified alveolar macrophage progenitors in human fetal liver that expressed the GM-CSF receptor CD116 and the transcription factor MYB.
    [Journal of Experimental Medicine]

    Full ArticleGraphical Abstract

    PDGF-D−PDGFRβ Signaling Enhances IL-15–Mediated Human Natural Killer Cell Survival

    The authors reported an additional but previously unknown role of PDGF-D, whereby it mediated interleukin-15–induced human NK cell survival but not effector functions via its binding to PDGFRβ but independent of its binding to NKp44.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Demethylase JMJD2D Induces PD-L1 Expression to Promote Colorectal Cancer Immune Escape by Enhancing IFNGR1-STAT3-IRF1 Signaling

    Scientists reported that both PD-L1 and JMJD2D were frequently overexpressed in human colorectal cancer specimens with a significant positive correlation.
    [Oncogene]

    Abstract

    Highly Efficient PD-1-Targeted CRISPR-Cas9 for Tumor-Infiltrating Lymphocyte-Based Adoptive T Cell Therapy

    Non-viral/plasmid-based programmed cell death protein 1 (PD-1) knockout was carried out immediately prior to the traditional 14-day tumor-infiltrating lymphocytes-based ACT rapid expansion protocol.
    [Molecular Therapy Oncolytics]

    Abstract

    Cytoplasmic Zinc Promotes IL-1β Production by Monocytes and Macrophages through mTORC1-Induced Glycolysis in Rheumatoid Arthritis

    Investigators demonstrated that cytoplasmic, bioavailable zinc was essential for promoting IL-1β production in activated human monocytes and macrophages downstream of glycolysis induced by the kinase-containing multiprotein complex mTORC1.
    [Science Signaling]

    Abstract

    Circulating CD8+ Mucosal-Associated Invariant T Cells Correlate with Improved Treatment Responses and Overall Survival in Anti-PD-1-Treated Melanoma Patients

    Researchers analyzed the frequency and functional profile of circulating and tumor-infiltrating mucosal-associated invariant T cells in human melanoma patients. Using flow cytometry, they compared these across metastatic sites and between ICI responders vs. non-responders as well as healthy donors.
    [Clinical & Translational Immunology]

    Full Article

    Functional Characterization of the Biogenic Amine Transporters on Human Macrophages

    The authors investigated the function of norepinephrine and dopamine transporters on human monocyte-derived macrophages.
    [JCI Insight]

    Abstract

    Reinvestigation of Classic T Cell Subsets and Identification of Novel Cell Subpopulations by Single-Cell RNA Sequencing

    Scientists integrated six bead-enriched T cell subsets with 62,235 single-cell transcriptomes from human PBMCs and clustered them into nine scRNA-seq clustered populations.
    [Journal of Immunology]

    Full ArticleGraphical Abstract

    Adenosine Receptor A2a Blockade by Caffeine Increases IFN–Gamma Production in Th1 Cells from Patients with Rheumatoid Arthritis

    Peripheral blood mononuclear cells were obtained from the peripheral blood of healthy individuals and patients with rheumatoid arthritis.
    [Scandinavian Journal of Rheumatology]

    Abstract

    Flowcytometry in Reactive Lymph Node Aspirates: Evaluation of Distribution of Populations with Immunophenotypic Outliers

    Flowcytometry of FNA/ scrape material from 30 cases of benign lymph nodes were evaluated to study the distribution of lymphoid populations and assess presence and percentages of immunophenotypic outliers.
    [Cytopathology]

    Abstract
    Daniel Grey investigates cell death modification as a potential therapy for immune disorders. View his profile.
    REVIEWS

    Programmed Cell Death 1 Ligand 1 Signals in Cancer Cells

    The authors discuss historical and recent advances in understanding cancer cell-intrinsic PDL1 signals, mechanisms for signal controls and important immunopathologic consequences including resistance to cytotoxic agents, targeted small molecules and immunotherapies.
    [Nature Reviews Cancer]

    Abstract

    Neutrophils in Chronic Inflammatory Diseases

    Investigators highlight the interaction of neutrophils with other cells in the context of chronic inflammation, the contribution of neutrophils to selected chronic inflammatory diseases, and possible future therapeutic strategies.
    [Cellular & Molecular Immunology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

    Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.
    [Rubius Therapeutics, Inc.]

    Press Release

    Evaxion Biotech Receives Regulatory Clearance to Initiate Phase II Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

    Evaxion Biotech A/S announced it received clearance from the Australia Therapeutic Goods Administration to initiate a Phase IIb trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s anti-PD-1 therapy KEYTRUDA®.
    [Evaxion Biotech A/S]

    Press Release

    FEATURED EVENT

    Immuno US

    February 7 – 8, 2022
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Senior Researcher – Biology

    UK Research and Innovation – Oxfordshire, England, United Kingdom

    Scientist – CART T Cell Cancer Immunotherapies

    Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States

    Project Manager – Therapeutic Development Branch

    National Institute of Health – Rockville, Maryland, United States

    Postdoctoral Research Associate – iPSC-Based Technologies for Immunotherapies

    Wisconsin National Primate Research Center – Madison, Wisconsin, United States

    Postdoctoral Fellowship – Breast Cancer Immunology

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter